|Day's Range||224.10 - 226.06|
|52 Week Range||184.50 - 261.27|
|PE Ratio (TTM)||7.01|
|Dividend & Yield||2.80 (1.27%)|
|1y Target Est||N/A|
Aerie Pharmaceuticals, Inc. (AERI) announced positive primary efficacy results of the 90-day phase III registration trial -- Mercury 2 -- for its pipeline candidate Roclatan.
Here's what I'm trading today amid the 'flat with a positive tone' action.
Here are the three CEOs who got the biggest pay raises last year, and the deepest pay cuts, as calculated by The Associated Press and Equilar, an executive data firm. ___ Top raises: ___ 1. Hock Tan Broadcom ...